Skip to main content

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.

Publication ,  Journal Article
Heiser, A; Coleman, D; Dannull, J; Yancey, D; Maurice, MA; Lallas, CD; Dahm, P; Niedzwiecki, D; Gilboa, E; Vieweg, J
Published in: J Clin Invest
February 2002

Autologous dendritic cells (DCs) transfected with mRNA encoding prostate-specific antigen (PSA) are able to stimulate potent, T cell-mediated antitumor immune responses in vitro. A phase I trial was performed to evaluate this strategy for safety, feasibility, and efficacy to induce T cell responses against the self-protein PSA in patients with metastatic prostate cancer. In 13 study subjects, escalating doses of PSA mRNA-transfected DCs were administered with no evidence of dose-limiting toxicity or adverse effects, including autoimmunity. Induction of PSA-specific T cell responses was consistently detected in all patients, suggesting in vivo bioactivity of the vaccine. Vaccination was further associated with a significant decrease in the log slope PSA in six of seven subjects; three patients that could be analyzed exhibited a transient molecular clearance of circulating tumor cells. The demonstration of vaccine safety, successful in vivo induction of PSA-specific immunity, and impact on surrogate clinical endpoints provides a scientific rationale for further clinical investigation of RNA-transfected DCs in the treatment of human cancer.

Duke Scholars

Published In

J Clin Invest

DOI

ISSN

0021-9738

Publication Date

February 2002

Volume

109

Issue

3

Start / End Page

409 / 417

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Transfection
  • T-Lymphocytes, Cytotoxic
  • Safety
  • RNA, Messenger
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Male
  • Immunotherapy, Active
  • Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M. A., Lallas, C. D., … Vieweg, J. (2002). Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest, 109(3), 409–417. https://doi.org/10.1172/JCI14364
Heiser, Axel, Doris Coleman, Jens Dannull, Donna Yancey, Margaret A. Maurice, Costas D. Lallas, Philipp Dahm, Donna Niedzwiecki, Eli Gilboa, and Johannes Vieweg. “Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.J Clin Invest 109, no. 3 (February 2002): 409–17. https://doi.org/10.1172/JCI14364.
Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 2002 Feb;109(3):409–17.
Heiser, Axel, et al. “Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.J Clin Invest, vol. 109, no. 3, Feb. 2002, pp. 409–17. Pubmed, doi:10.1172/JCI14364.
Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 2002 Feb;109(3):409–417.

Published In

J Clin Invest

DOI

ISSN

0021-9738

Publication Date

February 2002

Volume

109

Issue

3

Start / End Page

409 / 417

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Transfection
  • T-Lymphocytes, Cytotoxic
  • Safety
  • RNA, Messenger
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Male
  • Immunotherapy, Active
  • Immunology